Anika Begay
- Annual General Meeting Elects New Board of Directors: Dr. Frederick D. Sancilio, Dr. Harry Jacobson and Mr. Wesley Ramjeet
- Board of Directors Announces Resignation of CEO Philip Young and COO Baxter (NYSE:) Phillips III
- Board of Directors Appoints Dr. Frederick D. Sancilio as President and CEO of the Company
- Mr Rick Goulburn has been appointed to the Council as the fourth member
- Mr. Jeremy Wright joins the company as a director of the board of directors
VANCOUVER, British Columbia–(BUSINESS WIRE)–Lobe Sciences Ltd (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF)a biopharmaceutical company focused on developing products to treat diseases with high unmet medical needs, today announced that a new board of directors (Board) was elected at the Company’s annual general meeting, with shareholders electing the three previously announced nominees: Dr. Frederick D. Sancilio, Dr. Harry Jacobson and Mr. Wesley Ramjeet. Lobe Sciences also announces that Mr. Philip Young and Mr. Baxter Phillips have elected to leave the Company to pursue other opportunities. The Board has appointed Dr. Sancilio as Chairman of the Board and Chief Executive Officer of the Company.
Dr. Sancilio, Chairman and Chief Executive Officer, said, “While I regret the departure of Mr. Young and Mr. Phillips, I am excited about the opportunity to execute plans focused on creating shareholder value while meeting the needs of patients with serious unmet medical needs.”
The Company also announces the appointment by the Board of Directors of Mr. Rick Goulburn as a fourth member. Mr. Goulburn is expected to assume a leadership role as the Company moves toward its strategic goals. Finally, Lobe Sciences announces the appointment of Mr. Jeremy Wright as Executive and Board Director. Mr. Wright will provide guidance to the Company and its Board on strategic and administrative matters.
About Lobe Sciences Ltd.
Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with high unmet medical needs. The company, through collaboration with industry-leading partners, is engaged in novel research and development focused on the treatment of chronic cluster headache (an orphan disease), refractive anxiety, opioid addiction and sickle cell disease. The company is engaged in Phase 1 and Phase 2 activities across its portfolio of medicines and intends to initiate the launch of Altemia ®, a medical food designed to address the needs of sickle cell disease patients globally.
www.lobesciences.com
NEITHER THE CANADIAN CURRENCY EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Cautionary statement regarding “forward-looking” information
This press release includes certain statements and information that may constitute forward-looking information under applicable Canadian securities laws. All statements in this press release, other than statements of historical fact, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the Company’s intention to implement plans focused on creating shareholder value while meeting the needs of patients with serious unmet medical needs; the anticipated focus of the Company’s research and development activities; and the anticipated launch of Altemia® are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as intends or anticipates, or variations of such words and phrases, or statements that certain actions, events or results may, could, should or would occur.
Forward-looking statements are based on certain material assumptions and analyses made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company’s planned activities will be able to create value for shareholders and address serious unmet medical needs; the Company will continue to pursue its planned research and development activities; and the Company will launch Altemia®. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause the Company’s actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that could cause actual results to vary include, without limitation, the risk that: the Company’s planned activities will not be able to create value for shareholders or address targeted unmet medical needs; the Company will not be able to achieve the desired results from its current research and development activities; and the Company will not be able to launch Altemia® or to do so in the expected timeframe.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results to differ materially from those anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those projected in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook incorporated by reference herein except in accordance with applicable securities laws.
View original version on businesswire.com: https://www.businesswire.com/news/home/20240812177123/en/
For more information:
Dr. Fred D. Sancilio, CEO
Public limited company
Investors and media
Information@Lobesciences.com
Source: Lobe Sciences Ltd
